Flecainide is a prescription medication used to prevent certain types of abnormal heart rhythms, particularly episodes of atrial fibrillation and fast heart rhythms originating above or below the heart’s main pumping chambers. It works by slowing electrical signals in the heart, making it harder for erratic rhythms to start or sustain themselves. Importantly, flecainide is only appropriate for people without significant structural heart disease, a distinction that shapes nearly every prescribing decision around this drug.
Approved Uses for Flecainide
Flecainide is FDA-approved for three main categories of heart rhythm problems, all in people whose hearts are structurally normal:
- Paroxysmal atrial fibrillation or atrial flutter: episodes of irregular, often rapid heartbeats in the upper chambers of the heart that come and go. This is probably the most common reason flecainide is prescribed. The key word is “paroxysmal,” meaning the episodes start and stop on their own rather than being constant. Flecainide is not recommended for chronic (persistent) atrial fibrillation.
- Paroxysmal supraventricular tachycardia (PSVT): a group of conditions where an abnormal electrical circuit in or near the upper chambers of the heart causes sudden episodes of very fast heartbeat. This includes rhythms caused by an extra electrical pathway between the upper and lower chambers.
- Life-threatening ventricular arrhythmias: dangerous fast rhythms originating in the lower chambers of the heart, such as sustained ventricular tachycardia. This use is reserved for situations where the arrhythmia is considered life-threatening, not for milder or symptom-free ventricular rhythm problems.
For all of these conditions, flecainide is a preventive medication. You take it regularly to reduce the frequency and severity of episodes, not as a one-time fix during an active episode (though some people do use a single dose strategy called “pill in the pocket” under their doctor’s direction for occasional atrial fibrillation episodes).
How Flecainide Works
Flecainide belongs to a group of heart rhythm drugs classified as class IC antiarrhythmics. It works by blocking sodium channels in heart muscle cells. Sodium channels are the tiny gateways that allow electrical signals to fire and spread through the heart. By blocking them, flecainide slows the speed at which electrical impulses travel through heart tissue, which makes it much harder for abnormal circuits or rogue electrical signals to trigger a fast, chaotic rhythm.
Unlike some other sodium channel blockers, flecainide preferentially blocks channels when they’re in their active, open state. This means it has a stronger effect on heart tissue that’s firing rapidly (as during an arrhythmia) than on tissue beating at a normal rate. That selectivity is part of why it’s effective at suppressing abnormal rhythms while still allowing normal heartbeats to continue.
One measurable effect of this mechanism: flecainide widens the QRS complex on an ECG, which reflects the slower conduction speed. This widening is something your care team monitors closely, because too much slowing can itself become a problem.
The CAST Study and Structural Heart Disease
Flecainide carries a prominent safety warning rooted in a landmark clinical trial from the late 1980s. The Cardiac Arrhythmia Suppression Trial (CAST), funded by the National Heart, Lung, and Blood Institute, tested whether suppressing mild ventricular arrhythmias after a heart attack would improve survival. The results were the opposite of what researchers expected.
Among patients who had suffered a heart attack within the previous two years, those taking flecainide had a cardiac death or cardiac arrest rate of 5.1% over an average of ten months, compared to 2.3% in the placebo group. The trial was stopped early because the drug was clearly causing harm in this population.
This finding reshaped how flecainide is used. The drug now carries a black box warning, the most serious type of FDA safety alert, and is restricted to patients without structural heart disease (conditions like prior heart attack, heart failure, or significant thickening or scarring of the heart muscle). In children with structural heart disease, flecainide has been linked to cardiac arrest and sudden death. There is also no evidence that flecainide improves survival or reduces the risk of sudden death in any patient population. Its purpose is purely to reduce arrhythmia episodes and improve quality of life.
Who Should Not Take Flecainide
The most important restriction is structural heart disease. If you’ve had a heart attack, have heart failure, or have significant abnormalities in your heart’s structure or function, flecainide is generally off the table. Before prescribing it, your care team will typically confirm that your heart’s pumping function is normal, often with an echocardiogram.
Flecainide can also cause a dangerous situation in people with atrial flutter. The drug can slow the flutter rate just enough that the heart’s natural gatekeeper (the AV node) allows more impulses through to the lower chambers, paradoxically speeding up the heart rate. For this reason, flecainide is usually prescribed alongside another medication that slows conduction through the AV node, such as a beta blocker or calcium channel blocker.
People with significant kidney or liver impairment need careful dose adjustments because the body clears flecainide more slowly when these organs aren’t functioning well, which can lead to drug buildup and toxicity.
Typical Dosing
For atrial fibrillation and supraventricular tachycardias, the usual starting dose is 50 mg taken twice daily. For life-threatening ventricular arrhythmias, the starting dose is higher at 100 mg twice daily. Doses can be increased in steps of 50 mg twice daily, but adjustments happen no more often than every four days because it takes two to three days for the full effect of any given dose to become apparent.
The maximum daily dose for supraventricular arrhythmias is 300 mg. For ventricular arrhythmias, most people need no more than 300 mg daily, though the absolute ceiling is 400 mg.
Common Side Effects
The most frequently reported side effects reflect flecainide’s effects on the heart and nervous system. Dizziness, lightheadedness, and feeling faint are common, particularly when starting the medication or after dose increases. Some people notice blurred vision or see spots, a visual disturbance that often improves as the body adjusts to the drug over time.
Breathing-related symptoms, including shortness of breath, chest tightness, and wheezing, are also reported with some frequency. A fast or pounding heartbeat can occur, which is ironic for an antiarrhythmic drug but reflects its potential to provoke new rhythm problems (a phenomenon called proarrhythmia). This proarrhythmic risk is one of the main reasons flecainide is started under close medical supervision rather than casually prescribed.
Monitoring During Treatment
Starting flecainide typically happens in a hospital or clinical setting where your heart rhythm can be watched on a monitor. ECG recordings are checked every two to four days at the beginning of treatment and after any dose change. The key measurement your care team watches is the QRS duration on the ECG. If it widens by more than 25% compared to your baseline reading, the dose needs to be reduced or the drug stopped until the ECG returns to normal.
Blood levels of flecainide may also be checked, particularly in people with kidney or liver problems, to make sure the drug isn’t accumulating to unsafe concentrations. Once you’re on a stable dose and tolerating it well, monitoring becomes less intensive, but periodic ECGs remain part of ongoing care.